EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of Novel TLR2 Agonists for Regulating Tumor Microenvironment in Immunotherapy of Lung Cancer

Yue Pan, Qiuyue Fu, Zhuoxian Cao, Guibin Qiao, Kui Cheng iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c02158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Yue Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hong Kong-M…. Hauptthemen laut MEDLINE: Toll-Like Receptor 2, Immunotherapy, Tumor Microenvironment, Drug Design. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptor 2 (TLR2) agonists hold great promise for cancer immunotherapy. Our previously identified TLR2 agonist SMU-Z1 contains a nitro group associated with potential metabolic toxicity. Herein, 47 analogs were designed and synthesized to mitigate toxicity, and SMU-H1 emerged as a potent, selective TLR2 agonist (EC50 = 5.14 ± 0.7 nM) with superior safety relative to SMU-Z1. Mechanistically, SMU-H1 binds TLR2 to recruit MyD88, activates the MAPK/NF-κB pathways, and induces proinflammatory cytokines. TLR2 dependence was confirmed for the first time using TLR2-knockout mice. SMU-H1 also drives M1 macrophage polarization and dendritic cell activation via TLR2. In vivo, SMU-H1 enhanced immune cell activation and improved antitumor efficacy when combined with conventional anticancer drugs. Overall, SMU-H1 retains robust TLR2 agonistic activity with reduced toxicity, representing a promising candidate for cancer immunotherapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 2ImmunotherapyTumor MicroenvironmentDrug DesignLung NeoplasmsAntineoplastic AgentsAnimalsToll-Like Receptor AgonistsHumansMiceMice, KnockoutMice, Inbred C57BLCell Line, Tumor

Stichwörter der Autor:innen

TLR2 agonistToll-like receptorinflammatory factorstumor immunity

Substanzen

Toll-Like Receptor 2Toll-Like Receptor AgonistsAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
  • Department of Thoracic Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou510280, People's Republic of China.

ORCID-Profile: Kui Cheng

Förderung

  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Pan, Y., Fu, Q., Cao, Z., Qiao, G., & Cheng, K. (2026). Design and Synthesis of Novel TLR2 Agonists for Regulating Tumor Microenvironment in Immunotherapy of Lung Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02158

Vancouver

Pan Y, Fu Q, Cao Z, Qiao G, Cheng K. Design and Synthesis of Novel TLR2 Agonists for Regulating Tumor Microenvironment in Immunotherapy of Lung Cancer. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02158

BibTeX
@article{Pan2026,
  author = {Pan, Yue and Fu, Qiuyue and Cao, Zhuoxian and Qiao, Guibin and Cheng, Kui},
  title = {Design and Synthesis of Novel TLR2 Agonists for Regulating Tumor Microenvironment in Immunotherapy of Lung Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02158}
}
Kostenlos starten →